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TECHNICAL NOTE
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Glomerular ifitration rate measurement by "single-shot" injection of
Inulin. In 14 ADPKD patients the total body clearance and the urinary
clearance of inulin using the constant infusion method were compared
with the "single-shot" technique. Triplicate measurements of both
clearances by each infusion method were obtained in 12 out of 14
patients. A high correlation was found between the total body clearance
and the urinary clearance for both the constant infusion method (r =
0.96) and the single injection technique (r = 0.96). The coefficient of
variation for the total body clearance of inulin was significantly lower
for the constant infusion method and the single injection technique
(7.8% and 7.1%) than for the urinary clearance of inulin (11.3% vs.
9.7%, P < 0.05). A constant overestimation of the urinary clearance by
the total body clearance was observed with both methods (constant
infusion method 8.3 ml min' . 1.73 m2 and single injection tech-
nique 13.4 ml min 1.73 m2). No concentration-dependent clear-
ance was present. Determination of plasma inulin, especially at low
levels, showed substantial interference by glucose. We conclude that,
taking into account a constant overestimate of urinary clearance by the
total body clearance of inulin, the single injection total body clearance
possesses the best reproducibility and shows a good agreement with
the conventional urinary clearance, which can be calculated by: GFR =
TBCLss — 13.1 ml min' . 1.73 m2 (in the range of 28 to 124
ml min' . 1.73 m2).
It is well recognized that serum creatinine and even creati-
nine clearance are of limited value for assessing the level of
renal function and the rate of progression of renal disease [1—81.
Thus, an increasing number of investigators use the glomerular
rate (GFR) as a more accurate measuare to evaluate the efficacy
of interventions aimed at preventing or retarding the progres-
sion of renal failure [9—131.
GFR is measured using a variety of methods and filtration
markers. Urinary clearance of inulin, using a constant infusion,
has long been recognized as the "gold standard" [2]. Several
difficulties with this method have led to the development of
alternative methods [5, 14—16]. First, glucose interferes with the
measurement of inulin. Second, adequate collection of urine is
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a major practical problem, limiting the reproducibility of the
constant infusion and other urinary clearance methods. Inter-
estingly, limited data are available about the reproducibility of
the "gold standard" and alternative techniques in the same
patient groups [17]. For measuring the progression of renal
failure the reproducibility of the GFR measurement within an
individual is of key importance, as this will strongly influence
the needed sample size of intervention studies [18].
The primary aim of the present study was to define and
compare the agreement and reproducibility of the single intra-
venous injection of inulin with the method using a constant
infusion of inulin.
Methods
The study was approved by the Medical Ethics Committee of
the University Hospital Leiden.
Subjects
Fourteen patients with autosomal-dominant polycystic kid-
ney disease (ADPKD), defined by positive family history and
characteristic abnormalities on sonography, and three patients
with non-insulin dependent diabetes mellitus (NIDDM) were
studied (Table 1). All gave informed consent prior to the study.
None of the participants took drugs (other than oral contracep-
tives in the case of females) on the study days. Antihyperten-
sive treatment was discontinued for at least one week.
Study design
In 12 patients with ADPKD the clearance of inulin was
measured three times with the constant infusion method and
three times with a single intravenous injection technique on
separate occasions over the course of six weeks. Every other
week one constant infusion and one single injection technique
of inulin, in random order, was performed and these values
were used for comparison. To study the clearance of inulin at
high plasma levels, in three of these patients (patients 1, 2, and
3; Table 1) the constant infusion was repeated 12, 12, and 7
months after the initial measurements, with a five- to sixfold
loading and maintenance dose of inulin. The remaining two
ADPKD patients had one single intravenous injection and one
constant infusion of inulin in random order. In these patients,
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Table 1. Clinical characteristics of patients
Patient no. Diagnosis
Age
years Sex
Body weight
kg
BSA
m2
Serum creatinine
.unol/liter
Creatinine clearance
ml/min/1.73 m2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
ADPKD
NIDDM
NIDDM
NIDDM
43.8
33.0
34.1
40.0
47.3
62.2
57.7
43.7
67.4
26.5
36.6
29.4
38.4
68.8
59.6
57.8
67.5
f
m
f
m
f
f
f
f
m
f
m
m
f
m
in
f
m
62.0
73.0
81.5
80.0
72.0
75.0
76.5
64.0
84.0
67.5
80.0
81.0
52.0
80.0
75.0
121.0
78.5
1.7
1.9
1.9
2.1
1.7
1.8
1.9
1.8
2.1
1.8
2.0
2.0
1.6
1.9
1.9
2.4
2.0
197
181
84
94
133
127
70
69
146
82
119
142
80
210
244
109
147
36
39
89
104
40
47
86
99
42
97
70
89
56
44
25
46
50
Abbreviations
surface area.
are: ADPKD, autosomal-dominant polycystic kidney disease; NIDDM, non-insulin dependent diabetes mellitus; BSA, body
inulin was assayed with the specific inulinase method [19]. To
study the influence of plasma glucose on the determination of
inulin by the non-specific anthrone method, three patients with
non-insulin dependent diabetes mellitus were administered a
single intravenous injection of inulin and infused 25 grams
glucose during the elimination phase, from t = 180 until t = 200
minutes.
Inulin clearance measurements
All patients fasted on each study day from 0.00 hours until the
end of the inulin clearance measurement. After awakening, they
drank 500 ml of water and reported to the unit at 08.30 hours.
Twenty-four-hour urine collection started after voiding. To
enhance diuresis in the ADPKD patients, 1 liter of glucose 5%
was infused in 30 minutes, prior to the start of the inulin
infusion. To ensure ample diuresis in diabetics, these patients
drank 1000 ml water prior to the start of the inulin infusion.
Each patient was studied in the same position, either supine or
sitting during each study day, except when voiding. The inulin
loading dose was determined using the calculated lean body
mass [20], as:
Loading dose (mg) = 400 * Inulin space (L) and
Inulin space (L) = 0.175 * Lean body mass (kg)
to achieve comparable plasma levels in all patients.
Single intravenous injection
Inulin (Inutest', Laevosan GmbH, Linz, Germany) was
infused at a constant rate over five minutes by a precise
volumetric infusion pump (Sage Instruments, Massachusets,
USA) after which the infusion line was flushed with saline. At 0,
5, 7, 10, 20, 40, 60, 90, 120, 140, 160, 180, 210 and 240 minutes,
6 ml of blood were collected from an antecubital vein, in the
arm opposite in which inulin was infused. The patients were
asked to void before and 60, 120, 180 and 240 minutes after the
start of the inulin infusion.
Constant infusion
After a loading dose, as described above, a constant infusion
was started at a rate adjusted to maintain plasma concentrations
of inulin at 300 mg/liter, calculated as:
Infusion rate (mg/mm) 0.3 * Cockcroft clearance (mllmin).
After equilibration for 70 minutes, four clearance studies were
performed, each lasting 30 minutes. The average of these four
clearances was taken for further analysis.
Laboratory methods
Plasma and urine were either stored at —20°Cand assayed for
creatinine and inulin within 72 hours, or stored at —70°C until
analysis. Serum and urine concentrations of creatinine were
determined by a standard autoanalyzer technique. Inulin in
plasma and urine samples of all patients, except the NIDDM
patients, were measured using a specific enzymatic method. In
this assay, inulinase hydrolyzes inulin to its fructose mono-
mers, followed by enzymatic conversion of fructose to glucose-
6-phosphate which can be determined with the aid of glucose-
6-P-dehydrogenase [19].
To study the interference of glucose on plasma inulin levels
measured with the anthrone method, the plasma and urine
samples of the patients with NIDDM were determined in this
non-specific colorimetric assay, with and without correction for
serum glucose. This procedure includes deproteinization, after
which inulin and glucose are measured in the same urine or
plasma sample by two parallel autoanalyzer units, one measur-
ing glucose with the standard method from Technicon using
hexokinase, and one measuring inulin after acid hydrolysis to
fructose using anthrone [21]. Inulin-like optical density of
glucose standards were used to construct a glucose correction
curve. Inulin concentrations of infused solutions were also
determined. Blank values of urine and plasma were used for
subtraction.
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UCL measured with C-infusion
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Fig. 1. The total body clearances (TBCL) of all individuals versus the
urinary clearances (UCL) during the constant infusion of inulin.
Included in the graph is the line of identity.
Pharmacokinetic analysis
Urinary clearances of inulin were obtained by dividing the
urinary amount of inulin excreted over time by the time-
averaged plasma concentration calculated with the trapezoidal
rule. Total body clearance of inulin during the single intrave-
nous injection was calculated by dividing the infusion dose with
the area under the curve, obtained by curve fitting. The plasma
decay curves were fitted to a two-compartment pharmacoki-
netic model with zero-order administration of the dose over five
minutes, using the SIPHAR program (Simed, Créteil, Cedex,
France). This method is based on two simultaneous exponential
processes with constant rate input, defined as:
A(l e_a1) * T)ealPha(t — T) B(l — eIta *T)ebeta(t — T)
+
alpha * T beta * T
where C the plasma inulin concentration at time t, T = the
duration of infusion, being five minutes, with A, alpha, B, and
beta being hybrid constants [22]. They were first obtained by
"peeling" and subsequently refined by iterative non-linear
regression analysis using the Powell minimization algorithm
with a weighting factor of l/(calculated concentration)2 Ini-
tially, all plasma values were used for curve fitting, followed by
the same procedure with seven samples, including the blank. In
this analysis, two values were taken to describe the distribution
phase and four samples to describe the elimination phase in the
time period of 90 to 180 minutes. Thus, the total amount of time
required for the single injection technique equalled the time
period used during the constant infusion clearance. The total
body clearance of inulin during the constant infusion was
calculated from the concentration of the infusate times infusion
rate, divided by the time-averaged plasma concentrations.
0
0 25 50 75 100 125 150
UCL measured with single shot
mI/mm/i. 73 m2
Fig. 2. The total body clearances (TBCL) of all individuals versus the
urinary clearances (UCL) during the single injection technique of
inulin. Included in the graph is the line of identity.
Plasma samples were obtained at the beginning and end of
every urinary collection period. All clearances were normalized
to a standard body surface area (BSA) of 1.73 m2, using the
DuBois-DuBois formula for BSA [231.
Statistics
All values are expressed as mean SD, except when speci-
fied otherwise. Correlation coefficients were used to describe
the strength of the relation between the single intravenous
injection technique and the constant infusion method of inulin.
Agreement of the total body clearance of inulin using the
intravenous injection technique and the urinary clearance of
inulin using the constant infusion method were evaluated by
limits of agreement and graphically represented as described by
Bland and Altman [24]. These limits of agreement represent the
range around the mean difference (D) between both methods in
which 95% of the values will be found. They are defined as D
1.96 * SD when the differences between both methods approx-
imate a Gaussian distribution. Reproducibility of both methods
was tested by comparison of the coefficients of variation using
the Kruskal-Wallis non-parametric test.
Results
Total body versus urinary clearance of inulin
Total body clearance of inulin overestimated urinary clear-
ance at all levels of GFR, both during constant infusion (Fig. 1
and Table 2) and single intravenous injection (Fig. 2 and Table
2). The degree of overestimation was not related to the level of
GFR (Figs. 1 to 3). The mean difference of single injection total
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body clearance minus urinary clearance during constant infu-
sion, was 13.1 ml min' • 1.73 m2 (Fig. 3). Limits of agree-
ment were —7.7 and 33.9 ml min1 1.73 m2. The overesti-
mation by the total body clearance of urinary clearance was on
average 8.3 ml mint 1.73 m2 when the constant infusion
method was used, and 13.4 ml min1 1.73 m2 for the single
injection technique. Correlation between total body and urinary
clearance of inulin was high, r = 0.96 during the constant
infusion, and r = 0.96 for the single injection technique. Inulin
recovery from the collected 24 hour urine was 88.2 17.4% in
case of the single-injection technique (Fig. 4).
Comparison of the single injection and constant infusion
methods
Urinary clearances of inulin measured with both methods did
not differ significantly; the same was observed for total body
clearances (Figs. 5 and 6). Mean creatinine clearances during
both methods were similar and not significantly different.
Because of the substantial number of samples (N = 14) used
in the single injection method, we studied the effect of reducing
the number of plasma samples to a similar number of plasma
samples used in the constant infusion method on the main
outcome parameter, that is, total body clearance of inulin.
Describing the distribution phase by two samples at t = 10 and
20 minutes, and the elimination phase by four plasma samples at
t = 90, 120, 160 and 180 minutes, an excellent agreement of total
body clearance of inulin calculated with the total body clear-
ance determined with all plasma samples was found (r = 0.996,
Fig. 7). An additional advantage of this reduced number of
samples is that it takes less time for performing a single
injection method (3 hr instead of 4 hr), equalling that of a
constant infusion procedure.
Reproducibility of the single injection and constant infusion
methods
The results of triplicate estimations of the inulin clearance by
both methods are shown in Table 2. Mean coefficient of
variation for total body clearance was 7.1% during single
intravenous injection and 7.8% during constant infusion, com-
pared with 9.7% and 11.3% for the respective urinary clear-
ances (Table 2). The variation coefficient of the total body
clearances and the urinary clearances of both methods differed
significantly (P < 0.05). The variation coefficient of the total
body clearance was not significantly different with 6.6 3.4%
when total body clearance during the single injection technique
was calculated with seven instead of 14 plasma samples.
Effect of five- to sixfold higher plasma inulin levels on urinary
mu/in clearance
To evaluate linearity of inulin kinetics, in three of the ADPKD
patients we repeated a constant infusion study with five- to sixfold
higher loading and maintenance doses of inulin. In all three
patients stable plasma concentrations were reached, with levels of
1337 to 1965 mg/liter. Urinary inulin clearance in these patients
(Patients 1 to 3; Table I), determined 12, 12 and 7 months after the
initial study period, and calculated as the mean of four individual
clearance periods, were similar to previous values (27.2, 35.3 and
90.9 m1 1pj11. 1.73 m2 respectively, which is 0.7, 1.0, and 2.2
ml miir1 1.73 m2, respectively, lower than in the initial
study).
Effect of glucose on plasma inulin values
To evaluate the influence of plasma glucose on plasma inulin,
determined by the anthrone method, and the clearance values,
the effect of an intravenous infusion of 50 ml glucose 50% over
20 minutes was examined during the elimination phase of inulin
(Fig. 8) in three NIDDM patients [mean 24-hr creatinine clear-
ance 40.5 8.0 ml min' 1.73 m2 (mean sEM)]. This
resulted in an increase of plasma glucose from 6.8 0.6
mmollliter to 13.2 0.2 mmollliter (mean SEM). The concom-
itant values of plasma inulin measured with the anthrone
method, uncorrected for glucose, rose from 121.7 23.0
mg/liter to 180.0 26.7 mg/liter (mean SEM). The interference
by glucose on urinary inulin clearance, especially in this time
period (that is, 180 to 240 mm) was substantial. With correction
for glucose, mean urinary inulin clearance was 43.6 3.1
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Table 2. Comparison of inulin clearances
Cv
Patient no. UCLci %
1 27.9 17.2
2 36.3 8.7
3 93.1 16.2
4 95.5 11.3
5 38.1 11.8
6 44.2 8.8
7 91.4 7.9
8 123.4 5.1
9 51.7 13.9
10 107.9 10.1
11 59.6 16.9
12 74.9 8.2
13 71.8 —
14 39.3 —
Mean 11.3
sn 3.9
TBCLci
27.3
46.1
113.6
107.2
51.0
43.3
92.2
136.9
53.7
128.9
65.2
82.3
71.2
41.1
CV
%
6.9
10.0
4.7
10.2
5.6
9.4
11.3
6.9
7.7
4.2
10.7
5.5
7.8
2.5
UCLss
27.1
34.8
98.6
88.6
39.8
52.0
80.4
111.4
56.0
110.9
62.3
77.5
72.2
45.2
CV
17.9
0.6
12.6
8.8
10.1
5.4
10.4
9.4
9.0
19.9
3.4
9.0
9.7
5.4
TBCLss
41.8
49.2
107.8
120.2
48.7
53.0
86.7
129.5
66.7
127.3
73.3
97.0
86.2
60.7
Cv
%
7.4
5.3
8.8
4.8
10.7
6.0
9.2
10.8
0.7
10.7
6.1
5.1
7.1
3.1
All clearances are expressed as ml/minll .73 m2. Abbreviations are: CV, variation coefficient; UCLci, urinary inulin clearance during constant
infusion; TBCLci, total body clearance during constant infusion; UCLss, urinary inulin clearance during single-shot; TBCLss, total body clearance
during single-shot.
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Fig. 3. Difference against mean for total body clearance during the
single injection (TBCLss) and urinary clearance during the constant
infusion method (UCLci). Dashed lines represent the limits of agree-
ment around the averaged difference.
UCL measured with single shot
mI/mm/I. 73 m
Fig. 4. Inulin recovery from 24-hour urine after a single intravenous
injection in relation to the observed urinary clearance (UCL).
TBCL measured with C-infusion
mI/mm/i. 73 m2
Fig. S. Comparison of total body clearances (TBCL) obtained with the
single intravenous injection and the constant infusion method. Also
depicted is the line of identity.
level of GFR, as shown in Figures 1 and 2. An overestimation
has also been observed for other glomerular filtration markers
like mTcDTPA and 51Cr-EDTA [15]. In the same study,
inulin urinary clearance was 43.6 mllmin (range 11.0 to 76,1
mllmin) in 20 patients and plasma clearance 53.8 mllmin (range
25.1 to 83.5 mI/mm) [15]. A similar degree of overestimation by
total body clearance over a broad range of GFR, leading to a
close correspondence of total body inulin clearance with the
classical endogenous creatinine clearance, was demonstrated
by Silkalns et al [25]. The overestimation of GFR by the total
body clearance has also been confirmed in subjects with a
normal renal function, their total body clearance being 144 15
ml/min and urinary clearance 125 20 ml/min [26]. The same
observation was recently extensively confirmed over a broad
range of GFR by Hellerstein et al [27], who suggested that this
may be the result of incomplete equilibration of inulin in the
extracellular volume, requiring 12 to 15 hours or possibly even
longer. Thus, penetration of inulin into the less permeable
components of the interstitial matrix of the extracellular fluid
compartment will be highest with increasing time. The resultant
overestimation of the urinary clearance by the total body
clearance will be less with the constant infusion technique than
with the single injection method, as measurement of GFR by
the constant infusion method starts after an equilibration period
of 70 minutes. This was confirmed by our data, the difference
between total body clearance and urinary clearance being
largest for the single injection technique (13.4 vs. 8.3
ml min 1.73 m2, P < 0.05). The additional observation that
inulin recovery in the 24 hour urine was complete fits well with
the explanation of incomplete equilibration of inulin in the
extracellular volume, as extrarenal inulin clearance would
result in incomplete inulin recovery.
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ml min 1.73 m2, and 28.9 9.4 ml minj 1.73 m2 (mean
sEM) without correction for glucose. Plasma inulin values were
practically identical with the extrapolated values (127.3 20.1
mg/liter vs. 121.7 18.8 mg/liter), when corrected for glucose.
Discussion
The main findings of this study are that: (1.) there is a
constant overestimation of urinary clearance by the total body
clearance derived from either the constant infusion method or
the single injection technique; (2.) there is a very close corre-
lation of the single injection total body clearance with the
urinary inulin clearance using the constant infusion method
("gold standard"); and (3.) the total body clearance of inulin
has a much better reproducibility than the urinary clearance of
inulin.
The degree of overestimation seems to be unrelated to the
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UCL measured with C-infusion
mI/mm/i. 73 m2
Fig. 6. Comparison of urinary clearances (UCL) obtained with the
single intravenous injection and the constant infusion method. Also
depicted is the line of identity.
In studying the single intravenous injection technique, uri-
nary inulin clearance during the first hour, including peak
plasma inulin levels, was similar to urinary clearance during
subsequent hours with low plasma inulin levels in the terminal
elimination phase. These results are in contrast with data
presented by Prescott et al, who reported that the elimination of
inulin is highly concentration-dependent in both healthy volun-
teers and patients with renal failure [28, 291. They found that
urinary inulin clearance decreased progressively and signifi-
cantly as plasma concentrations fell over time after a single
injection of inulin. In healthy volunteers this was already
apparent after two hours, in patients with renal failure approx-
imately after three hours, with plasma inulin levels in the range
of 100 mg/liter in healthy volunteers and somewhat higher in
patients with chronic renal failure. In a further extension of
their study, using a constant infusion of inulin with plasma
inulin levels between 35.2 6.9 mg/liter and 187 29.3 mg/liter
(means SD), urinary inulin clearances were again found to be
lower [29]. These findings could not be confirmed in our study.
A possible explanation for these discrepant findings could be
the difference in assaying methodology for inulin. The spectro-
photometric method of measuring inulin used by Prescott et al
is complicated by interference with carbohydrates, especially
glucose [30]. The amount of interference by endogenous sub-
stances is in the range of 5 to 15 mg/liter [31]. In our three
patients with non-insulin dependent diabetes mellitus, infusion
of glucose significantly increased inulin levels (Fig. 8). This
strengthens the observation that glucose in physiological con-
centrations interferes linearly with the determination of inulin
by the anthrone method [22]. The interference of glucose was
relatively largest when plasma inulin levels were 100 mg/liter or
less. As a consequence, erroneously low urinary inulin clear-
0 25 50 75 100 125 150 175
TBCL measured with single shot,
all samples, mI/mm/i. 73 in2
Fig. 7. Comparison of total body clearances (TBCL) obtained with the
single intravenous injection method, calculated with all samples (x-
axis) or seven plasma samples (y-axis). Also depicted is the line of
identity.
ances will be found, in particular during the elimination phase.
The studies [32—35] cited by Prescott et al, in favor of the
concentration-dependent urinary clearance of inulin used as-
says [36—38] in which interference of glucose is difficult to
exclude. We suggest that the presumed concentration-depen-
dent urinary clearance of inulin in these studies is most likely
based on interference by glucose in the anthrone method. This
notion is also supported by Jung, Klotzek and Schulze [39],
who removed glucose prior to the colorimetric measurement in
order to improve reliability of low plasma inulin levels. They
observed close correspondence of inulin levels measured by
both the colorimetric method and a specific enzymatic inulin
assay even with low plasma levels, which we could confirm
(Lentjes et al, unpublished observations), Finally, others [40]
repeating constant infusion urinary inulin clearance with careful
urine collection in stable patients, using plasma inulin levels
ranging from 147 mg/liter to 232 mg/liter and during the second
study ranging from 259 mg/liter to 491 mg/liter, also found no
significant difference in urinary inulin clearance. This confirms
our observation that urinary inulin clearance is not influenced
by the level of plasma inulin levels.
To study renal handling of inulin during high plasma levels, in
three ADPKD patients urinary clearance of inulin using plasma
levels during constant infusion up to 2000 mg/liter were re-
peated. Taking into account the time interval of 12, 12, and 7
months between both studies in these patients, GFR values
were completely comparable with the initial measurements at
much lower plasma inulin levels. This is in accordance with the
unchanging values of urinary clearance during the single intra-
venous injection, irrespective of high peak plasma levels or low
plasma levels during the terminal elimination phase. Using
higher inulin loading doses, toxicity or alteration of renal
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Fig. 8. Effect of changes in plasma glucose
on plasma inulin levels measured with the
anthrone method in three non-insulin
dependent diabetes mellitus patients. To
study the influence of changing plasma250 glucose levels on plasma inulin, 25 grams of
glucose was given intravenously from 180 till
200 minutes after infusing inulin.
function by higher inulin concentrations were not observed,
even using doses as large as 160 grams [411. Obviously, at
higher plasma inulin levels during the elimination phase less
methodological assaying errors associated with low plasma
inulin levels will be found.
From a clinical point of view it is most useful to know how
much a measurement with one method is likely to differ from
that obtained with another. This is expressed by the limits of
agreement [24]. A recent study [42] reviewing agreement limits
between different glomerular filtration markers found limits of
agreement between studies ranging from —5 to 25
ml' min'' 1.73 m2 and —34 to 36 ml . min ' 1.73 m2. In
comparing total body clearance of the single intravenous injec-
tion technique with the conventional urinary clearance mea-
sured with constant infusion of inulin, limits of agreement of
—7.7 to 33.9 ml ' min 1.73 m2 were found (Fig. 3). These
limits of agreement reflect both variability of the total body
clearance of the single intravenous injection technique and of
the urinary clearance measured with constant infusion of inulin.
This means that if one method has poor repeatability, the
agreement between the two methods is bound to be poor, too.
Thus, "when the old method is the variable one, even a new
method which is perfect will not agree with it" [24]. Further-
more, in our experiments, day to day variability and intra-
individual variability of GFR also contribute to the variability of
both methods. The difference between the total body clearance
of inulin using the single injection technique and the urinary
clearance obtained with the conventional constant infusion
method was on average 13.1 ml * min1 - 1.73 m2, and was not
related to the level of GFR. Taken together with the small
coefficient of variation of the total body clearance, this implies
that replacing the conventional urinary clearance with the total
body clearance of the single intravenous injection technique
will result in an improvement of the ability to detect differences
in decline of renal function. For intervention studies, this may
permit a considerable decrease in sample size without a loss of
power. However, when the exact level of GFR is required,
conventional urinary inulin clearance may be the best option,
although it can also be calculated by GFR = TBCLss — 13.1
ml ' min'' 1.73 m2 in the range of28 to 124 ml ' min'' 1.73
m2.
The reproducibility of the constant infusion of inulin and the
single intravenous injection was good. The coefficients of
variation of total body clearances were significantly smaller
than the coefficients of variation for urinary clearances, despite
rigorous hydration and careful urinary collections (Table 2).
Halving the number of plasma samples during the single intra-
venous injection method had no detrimental effect on reproduc-
ibility (CV of all samples 7.1% vs. 6.6% with the reduced
number of samples), while agreement was excellent (r =0.996,
Fig. 7).
In conclusion, the total body clearance of inulin using the
single intravenous injection method has a good reproducibility
over a wide range of GFR, and up to 2000 mg/liter is indepen-
dent of plasma inulin concentrations. We observed a constant
overestimation of urinary clearance by the total body clearance
independent of the level of GFR, permitting a simple correction
to estimate the urinary clearance of inulin. Careful attention is
required with regard to the interfering effect of plasma glucose
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on the determination of plasma inulin levels when the anthrone
method for determination of inulin is used.
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